NASDAQ:NGM
NGM Biopharmaceuticals Inc. Stock News
$1.54
+0 (+0%)
At Close: May 16, 2024
Fly Insider: IFF, Smartsheet among week's notable insider trades IFF;CQP;NGM;PSEC;CDLX;SMAR;XPO;PTON;NXRT;NFLX
05:05pm, Monday, 30'th Mar 2020
Fly Insider: IFF, Smartsheet among week's notable insider trades IFF CQP NGM PSEC CDLX SMAR XPO PTON NXRT NFLX
Daily Insider Ratings Round Up 3/25/20
02:25pm, Friday, 27'th Mar 2020
Tables of the top insider purchases and sales filed with the SEC on 3/25/20, based on dollar value. Dollar values often do not equate with significance when it
Daily Insider Ratings Round Up 3/23/20
01:47am, Wednesday, 25'th Mar 2020
Tables of the top insider purchases and sales filed with the SEC on 3/23/20, based on dollar value. Dollar values often do not equate with significance when it
NGM Biopharmaceuticals (NGM) Gets a Buy Rating from Stifel Nicolaus
09:23am, Sunday, 22'nd Mar 2020
Stifel Nicolaus analyst Derek Archila reiterated a Buy rating on NGM Biopharmaceuticals (NGM – Research Report) on March 18 and
B.Riley FBR Sticks to Its Buy Rating for NGM Biopharmaceuticals (NGM)
06:37am, Thursday, 19'th Mar 2020
In a report released today, Mayank Mamtani from B.Riley FBR reiterated a Buy rating on NGM Biopharmaceuticals (NGM), with a price target of $30.00. The
B.Riley FBR Sticks to Its Buy Rating for NGM Biopharmaceuticals (NGM)
06:36am, Thursday, 19'th Mar 2020
In a report released today,
Mayank Mamtani
from B.Riley FBR reiterated a
Buy
rating on NGM Biopharmaceuticals (
NGM
–
Research Report
), with a price target of
$30.00
. The company’s shares closed
NGM Bio Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Highlights
08:05pm, Tuesday, 17'th Mar 2020
--Successfully completed 24-week Phase 2 study (Cohort 4) of aldafermin in non-alcoholic steatohepatitis (NASH) patients, and announced topline results demonstrating positive.
B.Riley FBR Maintains a Buy Rating on NGM Biopharmaceuticals (NGM)
12:42pm, Monday, 16'th Mar 2020
In a report issued on March 13, Mayank Mamtani from B.Riley FBR maintained a Buy rating on NGM Biopharmaceuticals (NGM), with a price target of $30.00.
B.Riley FBR Maintains a Buy Rating on NGM Biopharmaceuticals (NGM)
12:42pm, Monday, 16'th Mar 2020
In a report issued on March 13,
Mayank Mamtani
from B.Riley FBR maintained a
Buy
rating on NGM Biopharmaceuticals (
NGM
–
Research Report
), with a price target of
$30.00
. The company’s shares cl
Bio Roundup: Pandemic Declared, Rubius Restarts, Kymera’s Cash & More
01:33pm, Friday, 13'th Mar 2020
The financial markets are tumbling, event cancellations are mounting, and sports leagues are suspending their seasons. March Madness is in full swing but
NGM Biopharmaceuticals, Inc. (NGM), a biotechnology company focused on developing transformative therapeutics for patients, today announced that, effective March 13, 2020, Aetna Wun Trombley, Ph.D. wi
Better Buy: Intercept Pharmaceuticals vs. Madrigal Pharmaceuticals
03:30pm, Monday, 09'th Mar 2020
These companies are developing drugs that target the one of the biggest threats from the obesity epidemic.
Daily Insider Ratings Round Up 3/4/20
06:53pm, Saturday, 07'th Mar 2020
Tables of the top insider purchases and sales filed with the SEC on 3/4/20, based on dollar value. Dollar values often do not equate with significance when it c
Daily Insider Ratings Round-Up 2/28/20
02:30pm, Tuesday, 03'rd Mar 2020
Tables of the top insider purchases and sales filed with the SEC on 2/28/20, based on dollar value. Dollar values often do not equate with significance when it
Bio Roundup: COVID-19 Trials, Esperion’s Approvals, NASH News & More
02:52pm, Friday, 28'th Feb 2020
Clinical trials have historically hewn to a rigid format. A trial is designed, conducted according to that design, and then results are analyzed. Making